Clinical use of antibodies cause life-threatening fungal infections: Study

Washington [US], June 15 (ANI): Researchers found some monoclonal antibodies used in clinical trials have been linked to life-threatening systemic fungal infections.
The study was published in Journal, 'Cell.'
Primary fungal infections have become more common around the world, and one unexpected phenomenon among the rise of fungi is the emergence of life-threatening conditions as a side effect of certain immunotherapies and small molecule kinase inhibitors.
In a new publication, a scientist at the Hackensack Meridian Centre for Discovery and Innovation (CDI) has identified the specific mechanistic cause of one such phenomenon, which will likely save lives.

The paper "C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection" appeared in the journal Cell on May 22.
"Our findings will assist clinicians in their understanding of how these life-threatening infections are emerging," said Jigar Desai, PhD, assistant member of the CDI, assistant professor of medical sciences at the Hackensack Meridian School of Medicine, and first author of the paper. "These findings may help doctors and scientists alike better understand how some of these cases arise - and how to avoid them."
The team of scientists established that the C5a protein, the penultimate effector constituent of the complement pathway, is key to the body's innate ability to fight systemic fungal infections. Additionally, the team also identified that enhanced complement pathway signature acts as a predictive biomarker for systemic candidiasis. With the use of animal models, patient data and sera, the team showed how C5a and its downstream effects are crucial for the body's immune cells, specifically neutrophils and macrophages, to clear the fungus Candida albicans when it has overtaken the body's natural defences.
Desai and the team - which includes colleagues from the National Institutes of Health, Duke University, and Mount Sinai, among others - showed this in stages, both in animal models and in patient serum, by isolating what roles the C5 plays.
In addition to uncovering induced complement signature as a potential biomarker for systemic candidiasis, this work will be highly impactful in the clinical setting, where complement C5-targeted therapeutics, such as the anti-C5 monoclonal antibodies eculizumab (as well as the C5a receptor inhibitor, avacopan) are the treatment of choice. In these settings, findings from this work emphasize the importance of vigilant surveillance for opportunistic fungal infections, where early diagnosis can improve patient outcomes.
"Our findings establish a new paradigm in immunobiology, demonstrating for the first time the direct critical role of cell-intrinsic complement generation for effective host defence against Candida," written by the authors. "The multifaceted translation of our work shows promise for the development of individualized risk stratification and prognostication strategies in patients at-risk for invasive fungal disease." (ANI)